Politico; July 15, 2025: This article describes the FDA panel on the risks and benefits of hormone therapy for menopause: breast cancer, heart disease,stroke, dementia. Zuckerman points out that the panel is one-sided, ignoring data on risks and not allowing public comments from patients or experts to ask questions or describe studies indicating cancer and other serious risks.
Read More »Our Interviews, Blogs & OpEds
The FDA’s misguided thinking on antibiotics
STAT, February 10, 2025: Why are so many people dying from infections? In this op-ed, Diana Zuckerman and John Powers discuss that the main problem isn’t antimicrobial resistance; the problem is the way antibiotics are studied and approved. Research shows we can save lives with better studies and FDA approval standards that focus on patients and not bugs.
Read More »Readers respond to mothers in treatment for opioid use disorder, pandemic models, and more
STAT, June 8, 2024: Our Letter to the Editor at STAT News disagreed with the first Opinion commentary urging more use of antipsychotics for dementia patients. We explain that these drugs too often kill older patients or serve as chemical straight jackets,
Read More »Medicare has different standards than the FDA. That’s how it should be
STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.
Read More »Are PIP rubber playgrounds safe for Kingston?
Kingston Wire, October 23, 2023: NCHR president Diana Zuckerman’s oped in the Kingston (NY) Wire explains the risks to children of lead and other toxic chemicals in PIP rubber playground surfaces and artificial turf in Kingston and other communities.
Read More »